2,3,5-Trimethylmorpholin | 98430-04-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 2,3,5-Trimethylmorpholin
• 英文别名: 2,3,5-trimethyl-morpholine；2,3,5-Trimethylmorpholine
• CAS: 98430-04-7
• 化学式: C₇H₁₅NO
• 分子量: 129.202
• InChiKey: XDAMZGXFTHZDFD-UHFFFAOYSA-N

物化性质

• 熔点：
  160-164 °C
• 沸点：
  165.1±15.0 °C(Predicted)
• 密度：
  0.841±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• 20-hydroxyeicosatetraenoic acid production inhibitors
  申请人：——

  公开号：US20040121997A1

  公开（公告）日：2004-06-24

  A hydroxyformamidine compound represented by the following formula or a pharmaceutically acceptable salt thereof. 1 [wherein R 1 represents a substituted morpholino group, a substituted piperidino group, a piperazin-1-yl group, a substituted piperazin-1-yl group, a thiomorpholin-1-yl group, a perhydroazepin-1-yl group, a perhydroazocin-1-yl group, a tetrahydropyridin-1-yl group, a pyrrolin-1-yl group, etc. ; X represents a nitrogen atom or a group represented by CR 5 ; and R 2 to R 5 are the same or different and each represents a hydrogen atom, a C 1-4 alkyl group, a C 1-4 alkoxy group, a trifluoromethyl group or a halogen atom.] There is provided a drug which inhibits an enzyme producing 20-HETE participating in a contracting or dilating action for microvessels and an inducing action for cell proliferation in main organs such as kidney and cerebrovascular vessels.

  提供一种羟基甲酰胺化合物，其化学式如下，或其药学上可接受的盐。其中，R1代表取代的吗啡啶基团、取代的哌啶基团、哌嗪-1-基基团、取代的哌嗪-1-基基团、硫代吗啡啶-1-基基团、过氢化氮杂丙环-1-基基团、过氢化氮杂环己-1-基基团、四氢吡啶-1-基基团、吡咯烷-1-基基团等；X代表氮原子或CR5所代表的基团；R2到R5相同或不同，每个代表氢原子、C1-4烷基、C1-4烷氧基、三氟甲基或卤素原子。提供一种药物，其抑制产生20-HETE的酶，参与微血管的收缩或扩张作用，并诱导主要器官如肾脏和脑血管的细胞增殖作用。
• 20-HYDROXYEICOSATETRAENOIC ACID PRODUCTION INHIBITORS
  申请人：TAISHO PHARMACEUTICAL CO., LTD

  公开号：EP1389611B1

  公开（公告）日：2012-06-27
• METHODS OF MODULATING CELL PROLIFERATION AND CYST FORMATION IN POLYCYSTIC KIDNEY AND LIVER DISEASES
  申请人：MCW Research Foundation, Incorporated

  公开号：EP2061450A2

  公开（公告）日：2009-05-27
• Methods of modulating cell proliferation and cyst formation in polycystic kidney and liver diseases
  申请人：Sweeney William E.

  公开号：US20080167382A1

  公开（公告）日：2008-07-10

  The present invention provides a method for preferentially reducing the proliferation of cystic epithelial cells in the kidney or bile duct in a mammal in need thereof by administering a 20-HETE synthesizing enzyme inhibitor or a 20-HETE antagonist to the mammal in an amount sufficient to preferentially reduce the proliferation of cystic epithelial cells over normal epithelial cells such as tubule epithelial cells in the kidney or bile duct. The present invention also provides a method for preventing or treating autosomal dominant polycystic kidney disease (ADPKD), autosomal recessive polycystic kidney disease (ARPKD), ARPKD associated congenital hepatic fibrosis, ARPKD associated Caroli's disease, or cholangiocarcinoma in a mammal in need thereof by administering a 20-HETE synthesizing enzyme inhibitor or a 20-HETE antagonist to the mammal in an amount sufficient to prevent or treat the disease.
• Methods of Modulating Cell Proliferation and Cyst Formation in Polycystic Kidney and Liver Diseases
  申请人：Sweeney William E.

  公开号：US20140329811A1

  公开（公告）日：2014-11-06

  The present invention provides a method for preferentially reducing the proliferation of cystic epithelial cells in the kidney or bile duct in a mammal in need thereof by administering a 20-HETE synthesizing enzyme inhibitor or a 20-HETE antagonist to the mammal in an amount sufficient to preferentially reduce the proliferation of cystic epithelial cells over normal epithelial cells such as tubule epithelial cells in the kidney or bile duct. The present invention also provides a method for preventing or treating autosomal dominant polycystic kidney disease (ADPKD), autosomal recessive polycystic kidney disease (ARPKD), ARPKD associated congenital hepatic fibrosis, ARPKD associated Caroli's disease, or cholangiocarcinoma in a mammal in need thereof by administering a 20-HETE synthesizing enzyme inhibitor or a 20-HETE antagonist to the mammal in an amount sufficient to prevent or treat the disease.